Given the significant metabolic burden associated with PCOS and the lack of reliable markers for monitoring treatment response, fetuin-B presents a promising candidate for evaluating the efficacy of pharmacological therapies targeting the metabolic component of PCOS. The gene discussed is FETUB; the disease is polycystic ovary syndrome.